Gilead Sciences, Inc.
GILDHealthcareNASDAQDrug Manufacturers - General · Last scanned Jul 18, 2026
Scan Results
Daily timeframeGilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The $166.72B market capitalization puts GILD squarely in large-cap range for its industry. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Market Cap
$166.72B
Beta
0.34
P/E (TTM)
18.55
P/E (Fwd)
13.83
EPS (TTM)
$7.24
EPS (Fwd)
$9.71
ROE
43.4%
ROA
13.3%
Cash
$9.82B
Total Debt
$22.17B
Free CF
$7.93B
52W Change
24.1%
Annual Financials
Cash vs Debt
The company holds $9.82B in cash, though total debt stands at $22.17B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $7.93B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 43.4% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 13.3% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $27.28B (2022) to $29.44B (2025).
With a beta below 0.7, Gilead Sciences, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Gilead Sciences, Inc.'s trajectory.